Literature DB >> 20563710

Varicella zoster virus immune evasion strategies.

Allison Abendroth1, Paul R Kinchington, Barry Slobedman.   

Abstract

The capacity of varicella zoster virus (VZV) to cause varicella (chickenpox) relies upon multiple steps, beginning with inoculation of the host at mucosal sites with infectious virus in respiratory droplets. Despite the presence of a powerful immune defense system, this virus is able to disseminate from the site of initial infection to multiple sites, resulting in the emergence of distinctive cutaneous vesiculopustular lesions. Most recently, it has been proposed that the steps leading to cutaneous infection include VZV infecting human tonsillar CD4(+) T cells that express skin homing markers that allow them to transport VZV directly from the lymph node to the skin during the primary viremia. It has also been proposed that dendritic cells (DC) of the respiratory mucosa may be among the first cells to encounter VZV and these cells may transport virus to the draining lymph node. These various virus-host cell interactions would all need to occur in the face of an intact host immune response for the virus to successfully cause disease. Significantly, following primary exposure to VZV, there is a prolonged incubation period before emergence of skin lesions, during which time the adaptive immune response is delayed. For these reasons, it has been proposed that VZV must encode functions which benefit the virus by evading the immune response. This chapter will review the diverse array of immunomodulatory mechanisms identified to date that VZV has evolved to at least transiently limit immune recognition.

Entities:  

Mesh:

Year:  2010        PMID: 20563710      PMCID: PMC3936337          DOI: 10.1007/82_2010_41

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  68 in total

Review 1.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Viral subversion of the immune system.

Authors:  D Tortorella; B E Gewurz; M H Furman; D J Schust; H L Ploegh
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 4.  Varicella-zoster virus open reading frame 66 protein kinase and its relationship to alphaherpesvirus US3 kinases.

Authors:  Angela Erazo; Paul R Kinchington
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

5.  Modulation of major histocompatibility class II protein expression by varicella-zoster virus.

Authors:  A Abendroth; B Slobedman; E Lee; E Mellins; M Wallace; A M Arvin
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells.

Authors:  A Abendroth; I Lin; B Slobedman; H Ploegh; A M Arvin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers.

Authors:  Chia-Chi Ku; Jorge A Padilla; Charles Grose; Eugene C Butcher; Ann M Arvin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host.

Authors:  A Abendroth; G Morrow; A L Cunningham; B Slobedman
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 9.  Immune evasion as a pathogenic mechanism of varicella zoster virus.

Authors:  A Abendroth; A M Arvin
Journal:  Semin Immunol       Date:  2001-02       Impact factor: 11.130

10.  Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection.

Authors:  Jennifer H Huch; Anthony L Cunningham; Ann M Arvin; Najla Nasr; Saskia J A M Santegoets; Eric Slobedman; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

View more
  23 in total

1.  Metabolic Phenotypes of Response to Vaccination in Humans.

Authors:  Shuzhao Li; Nicole L Sullivan; Nadine Rouphael; Tianwei Yu; Sophia Banton; Mohan S Maddur; Megan McCausland; Christopher Chiu; Jennifer Canniff; Sheri Dubey; Ken Liu; ViLinh Tran; Thomas Hagan; Sai Duraisingham; Andreas Wieland; Aneesh K Mehta; Jennifer A Whitaker; Shankar Subramaniam; Dean P Jones; Alessandro Sette; Kalpit Vora; Adriana Weinberg; Mark J Mulligan; Helder I Nakaya; Myron Levin; Rafi Ahmed; Bali Pulendran
Journal:  Cell       Date:  2017-05-11       Impact factor: 41.582

Review 2.  Molecular mechanisms of varicella zoster virus pathogenesis.

Authors:  Leigh Zerboni; Nandini Sen; Stefan L Oliver; Ann M Arvin
Journal:  Nat Rev Microbiol       Date:  2014-02-10       Impact factor: 60.633

3.  Tunneling Nanotubes as a Novel Route of Cell-to-Cell Spread of Herpesviruses.

Authors:  Mirosława Panasiuk; Michał Rychłowski; Natalia Derewońko; Krystyna Bieńkowska-Szewczyk
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

4.  In vivo confocal microscopy detects bilateral changes of corneal immune cells and nerves in unilateral herpes zoster ophthalmicus.

Authors:  Bernardo M Cavalcanti; Andrea Cruzat; Afsun Sahin; Deborah Pavan-Langston; Eric Samayoa; Pedram Hamrah
Journal:  Ocul Surf       Date:  2017-09-18       Impact factor: 5.033

5.  Varicella-zoster virus-derived major histocompatibility complex class I-restricted peptide affinity is a determining factor in the HLA risk profile for the development of postherpetic neuralgia.

Authors:  Pieter Meysman; Benson Ogunjimi; Stefan Naulaerts; Philippe Beutels; Viggo Van Tendeloo; Kris Laukens
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

6.  Immune correlates of herpes zoster in HIV-infected children and youth.

Authors:  Adriana Weinberg; Sharon Huang; Lin-Ye Song; Terry Fenton; Paige Williams; Julie Patterson; Adriana Tovar-Salazar; Myron J Levin
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

7.  Varicella-zoster virus inhibition of the NF-κB pathway during infection of human dendritic cells: role for open reading frame 61 as a modulator of NF-κB activity.

Authors:  Elizabeth Sloan; Rodney Henriquez; Paul R Kinchington; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

Review 8.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

9.  Immunological evasion of immediate-early varicella zoster virus proteins.

Authors:  Pieter Meysman; Dmitry Fedorov; Viggo Van Tendeloo; Benson Ogunjimi; Kris Laukens
Journal:  Immunogenetics       Date:  2016-03-29       Impact factor: 2.846

Review 10.  Prospects and perspectives for development of a vaccine against herpes simplex virus infections.

Authors:  Shane C McAllister; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2014-07-31       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.